Alkaline phosphatase (ALP) is present in human serum in the form of several isoenzymes.
The two major circulating ALP isoenzymes, bone and liver, are difficult to distinguish because they are the products of a single gene and differ only by posttranslational glycosylation. Quantitative measurement of bone ALP (BAP) activity in serum can provide an index for the rate of bone formation.
Furthermore, increased BAP activity in serum is indicative of bone disorders. We describe a method in which serum samples are added to a microtiter plate coated with monoclonal anti-BAP antibody and incubated 3 h at room temperature.
After the unbound materials are washed off, the bound BAP activity is measured by adding p-nitrophenyl phosphate substrate.
The assay demonstrated no cross-reactivfty to intestinal or placental ALP and only 3-8% cross-reactivity to liver ALP. The intraassay (n = 21) CV5 were 3.9-5.9%, and interassay (n = 8) CVs were 4.4-7.0%.
Comparisons of the assay (y) with an IRMA (x) and a wheat germ agglutinin precipitation method (x') gave regression equations of y = 1 .32x -6.4, r = 0.99, and y = 1 .41x' + 4.8, r = 0.99. The assay detected increased BAP in sera from patients with osteoporosis, Paget disease, osteomalacia, or primary hyperparathyroidism. 
Materials and Methods
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We analyzed sera from a group of healthy adults by the ETA to establish preliminary reference intervals. The total ALP activity of the sample was measured, and the sample was then precipitated with an agglutmnin from wheat germ. after which the ALP activity remaining in the supernate was measured. The comparison of total ALP and remaining ALP gave the BAP activity.
for metabolic bone disorders (35) and as a predictive marker for metastasis in bone (7, 36) . The ALP produced by osteoblasts is believed to be indicative of the bone mineralization process (7, 35, 36 
